Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 3 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF BEROTRALSTAT PROPHYLAXIS IN CHILDREN WITH HEREDITARY ANGIOEDEMA WHO ARE 2 TO < 12 YEARS OF AGE

Next Previous
Trial Profile

A PHASE 3 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF BEROTRALSTAT PROPHYLAXIS IN CHILDREN WITH HEREDITARY ANGIOEDEMA WHO ARE 2 TO < 12 YEARS OF AGE

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Berotralstat (Primary)
  • Indications Hereditary angioedema
  • Focus Pharmacokinetics; Registrational
  • Acronyms APeX-P
  • Sponsors BioCryst Pharmaceuticals

Most Recent Events

  • 11 Feb 2026 According to BioCryst Pharmaceuticals media release, interim data from the trial will be presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Philadelphia from February 27-March 2, 2026.
  • 12 Dec 2025 According to a BioCryst Pharmaceuticals media release, company has filed its application for the use of ORLADEYO oral pellets with the European Medicines Agency and the Japan Pharmaceutical and Medical Devices Agency. Additional regulatory filings are planned in other global territories, including Canada.
  • 12 Dec 2025 According to a BioCryst Pharmaceuticals media release, based on positive interim data from this APeX-P trial, the U.S. FDA has approved its New Drug Application (NDA) for the use of an oral pellet formulation of once-daily ORLADEYO (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE). A capsule formulation of ORLADEYO has received approval in December 2020 and is now approved in more than 45 countries around the world.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top